The Population Council mourns the death of Dr. Frederick T. Sai, reproductive rights champion and former Trustee of the Population Council.
NEW YORK, NEW YORK (September 10, 2019) – The Population Council has announced that Stephanie Psaki has become director of the Population Council’s Girl, Innovation, Research, and Learning (GIRL) Center – a collaborative global research hub dedicated to generating, synthesizing and disseminating evidence to transform the lives of the 1.2 billion adolescents worldwide.
In a video at Bloomberg's Tic Toc, Jim Sailer, Executive Director of the Population Council's Center for Biomedical Research (CBR), explains how the Council's Nestorone®/Testosterone (NES/T) transdermal male contraceptive gel works and speaks about the importance of gender equality in preventing pregnancy.
Mr. Martin Jeiven, a long-term collaborator of the Population Council’s Center for Biomedical Research (CBR), has pledged $100,000 to seed-fund a new fellowship program for laboratory scientists from Africa. Fellow will spend three months working alongside Population Council scientists in our laboratories at Rockefeller University before returning to their home institution to lead collaborations with CBR.
The Population Council has been conducting high-quality research to determine what works and what doesn’t work to empower girls and prevent child marriage for years. That expertise and our research in Ethiopia took center stage in a BBC World Service feature, in a featured piece at Voice of America, and in a blog post featuring Malala Yousafzai and her girls’ education advocacy organization, the Malala Fund.
Population Council researchers will share new research and insights on the latest in the HIV and AIDS epidemic at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City, Mexico July 20-24. IAS 2019 is the largest open conference on HIV science in the world.
NEW YORK, NEW YORK (June 20, 2019) – The Lancet Global Health today published results from the Phase 3 clinical efficacy trials of the Population Council-developed Annovera™ (segesterone acetate and ethinyl estradiol vaginal contraceptive system). Annovera is the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. Results show that Annovera was 97% effective in preventing pregnancy for up to 13 menstrual cycles, which means that women do not need to return to the clinic or pharmacy for prescription refills.
In response to a New York Times report on the dearth of women enrolled in H.I.V. clinical trials, Ruth Merkatz, director of clinical development at the Population Council’s Center for Biomedical Research and former director of the Office of Women’s Health at the FDA, wrote a letter to the editor about the essential need for gender equality in clinical trials.
The Population Council welcomes publication of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study. We congratulate the trial organizers and appreciate the more than 7,800 women in four countries in East and Southern Africa whose participation in the trial advances our understanding of women’s needs and choices in contraception and HIV prevention.
